Paraneoplastische neurologische Syndrome

Lernziele

Der vorliegende Artikel vermittelt einen Überblick über Epidemiologie, Pathophysiologie, Klinik, Diagnostik, Therapie und Verlauf der paraneoplastischen neurologischen Syndrome. Darüber hinaus werden die klassischen paraneoplastischen neurologischen Erkrankungen mit ihren assoziierten Tumoren und spezifischen onkoneuronalen Antikörpern ausführlicher dargestellt. Ziel ist es, fundierte Grundlagen zu vermitteln, um PNS klinisch zu erkennen, ihre rationelle Diagnostik zu planen und die Prinzipien der Behandlung zu kennen.

Literatur

• 1 Darnell R B, Posner J B. Paraneoplastic syndromes involving the nervous system.  N Engl J Med. 2003;  349 1543-1554
• 2 Posner J B. Paraneoplastic syndromes. In Davis F A, ed Neurologic complications of cancer.. Philadelphia: F. A. Davis; 1995: 353-385
• 3 Voltz R, Blaes F, Rauer S. Paraneoplastische Syndrome. In: Kommission „Leitlinien der Deutschen Gesellschaft für Neurologie”, (Hrsg.) Leitlinien für Diagnostik und Therapie in der Neurologie.. Thieme: Stuttgart; 2008: 809-815
• 4 Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS.  J Neurol. 2010;  257 509-517
• 5 Lang B, Waterman S, Pinto A et al. The role of autoantibodies in Lambert-Eaton myasthenic syndrome.  Ann N Y Acad Sci. 1998;  841 596-605
• 6 Newsom-Davis J, Mills K R. Immunological associations of acquired neuromyotonia (Isaacs’ Syndrome). Report of five cases and literature review.  Brain. 1993;  116 453-469
• 7 Polans A S, Witkowska D, Haley T L et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy.  Proc Natl Acad Sci. 1995;  92 9176-9180
• 8 Graus F, Delattre J Y, Antoine J C et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes.  J Neurol Neurosurg Psychiatry. 2004;  75 1135-1140
• 9 Gultekin S H, Rosenfeld M R, Voltz R et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.  Brain. 2000;  123 1481-1494
• 10 Dalmau J, Graus F, Villarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis.  Brain. 2004;  127 1831-1844
• 11 Dalmau J, Gleichman A J, Hughes E G et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.  Lancet Neurol. 2008;  7 1091-1098
• 12 Lai M, Hughes E G, Peng X et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location.  Ann Neurol. 2009;  65 424-434
• 13 Lai M, Huijbers M G, Lancaster E et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.  Lancet Neurol. 2010;  9 776-785
• 14 Vincent A, Buckley C, Schott J M et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.  Brain. 2004;  127 701-712
• 15 Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy.  Lancet Neurol. 2002;  1 294-305
• 16 Peterson K, Rosenblum M K, Kotanides H et al. Paraneoplastic cerebellar degeneration. A clinical analysis of 55 anti-Yo antibody positive patients.  Neurology. 1992;  42 1931-1937
• 17 Honnorat J, Antoine J C. Paraneoplastic neurological syndromes.  Orphanet J Rare Dis. 2007;  2 22
• 18 Gambini C, Conte M, Bernini G et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.  Virchows Arch. 2003;  442 555-562
• 19 Camdessanche J P, Antoine J C, Honnorat J et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients.  Brain. 2002;  125 166-175
• 20 De Giorgio R, Guerrini S, Barbara G et al. Inflammatory neuropathies of the enteric nervous system.  Gastroenterology. 2004;  126 1872-1883
• 21 O’Neill J H, Murray N M, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases.  Brain. 1988;  111 577-596
• 22 Bataller L, Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes.  Curr Opin Neurol. 2004;  17 3-8
• 23 Graus F, Keime-Guibert F, Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.  Brain. 2001;  124 1138-1148
• 24 Graus F, Dalmou J, Rene R et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.  J Clin Oncol. 1997;  15 2866-2872
• 25 Monstad S E, Knudsen A, Salvesen H B et al. Onconeural antibodies in sera from patients with various types of tumours.  Cancer Immunol Immunother. 2009;  58 1795-1800
• 26 Hoffmann L A, Jarius S, Pellkofer H L et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases.  J Neurol Neurosurg Psychiatry. 2008;  79 767-773
• 27 Antoine J C, Absi L, Honnorat J et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors [see comments].  Arch Neurol. 1999;  56 172-177
• 28 Tschernatsch M, Singh P, Gross O et al. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy.  J Neuroimmunol. 2010;  226 177-180
• 29 Bannas P, Weber C, Derlin T et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis.  Eur Radiol. 2010;  20 923-930
• 30 Stich O, Jarius S, Kleer B et al. Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes.  J Neuroimmunol. 2007;  183 220-224